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Abstract: Bardet-Biedl syndrome (BBS) is an autosomal recessive disorder characterized by central obesity, mental impairment, 
­ rod-cone­dystrophy,­polydactyly,­hypogonadism­in­males,­and­renal­abnormalities.­The­causative­genes­have­been­identified­as­BBS1-14.­
In­the­Western­countries,­the­prevalence­of­this­disease­ranges­from­1/13,500­to­1/160,000,­while­only­a­few­Japanese­patients­have­
been reported in the English-language literature. The incidence of renal dysfunction or anomalies in previous reports varies considerably 
ranging from ∼20%­to­universal­occurrence.­We­here­report­that­two­Japanese­patients­who­had­BBS­with­normal­BUN­and­creatinine­
levels­had­elevated­levels­of­cystatin­C,­a­sensitive­marker­of­glomerular­filtration­rate.­A­urine­albumin­level­increased­only­in­the­elder­
patient.­Thus,­cystatin­C­may­be­useful­for­detecting­renal­abnormalities­in­patients­with­an­apparent­normal­renal­function.­Because­this­
disease is diagnosed by accumulation of symptoms, such a sensitive marker might help early diagnosis of BBS.
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Introduction
Bardet-Biedl  syndrome  (BBS)  is  an  autosomal 
  recessive disorder characterized by central obesity, 
mental impairment, rod-cone dystrophy, polydactyly, 
hypogonadism in males, and renal abnormalities.1,2 
The­ causative­ genes­ have­ been­ identified­ as­
BBS1-14­genes­that­encode­proteins­possibly­linked­
to­cilia­function,­but­more­than­20%­of­patients­have­
no mutations found.3 The diagnosis is made only by 
the­clinical­phenotype­with­the­presence­of­at­least­
three­major­symptoms,­however,­it­is­often­difficult­
partly because of age-dependent development of some 
symptoms. In the Western countries, the prevalence 
of­this­disease­ranges­from­1/13,500­to­1/160,000.3 
By­contrast,­only­a­few­Japanese­patients­have­been­
reported in the English-language literature.4–6
Renal­ fibrosis­ is­ one­ of­ the­ most­ ­ devastating­
  symptoms,  ultimately  leading  to  chronic  renal 
  failure  requiring  hemodialysis.7  The  incidence 
of  renal  dysfunction  or  anomalies  in  previous 
reports    varies  considerably  ranging  from  ∼20%­
to    universal  occurrence.2,7­ An­ early­ detection­ of­
such   abnormalities may be important for patients 
and guardians to   prepare them. It may also be use-
ful for prompt   correct   diagnosis of BBS, since the 
diagnosis of this disease is based on the accumu-
lation of major symptoms as described above. We 
now­report­that­two­Japanese­patients­with­BBS­had­
normal­BUN­and­creatinine­level­but­elevated­lev-
els of   cystatin C, a sensitive marker of glomerular 
­ filtration­rate­(GFR).
patients
A­20-year-old­man­(patient­1)­had­mental­retardation­
(minimental­ state­ examination­ 23;­ normal­ .­ 24),­
­ rod-cone­dystrophy,­central­obesity­(height­158­cm,­
weight­ 63­ kg,­ and­ BMI­ 25.2)­ and­ hypogonadism­
since­ the­ age­ of­ 5­ years.­ His­ waist­ circumference­
was­83.5­cm.­His­blood­pressure­was­131/85­mmHg,­
and­his­heart­rate­was­61­beats/min.­He­had­normal­
heart­sounds­with­clear­breath­sounds.­A­­ 16-year-old­
boy­(patient­2),­the­younger­brother­of­patient­1,­had­
  polydactyly in addition to the symptoms described 
above­(height­165­cm,­weight­93­kg,­and­BMI­34.2).­
His­ waist­ circumference­ was­ 107­ cm.­ His­ blood­
­ pressure­was­128/61­mmHg,­and­his­heart­rate­was­
77­beats/min.­He­had­normal­heart­sounds­with­clear­
breath  sounds.  Their  non-consanguineous  parents 
were­apparently­healthy.­The­symptoms­of­patients­
and­probable­autosomal­recessive­­ inheritance­­ fulfilled­
the­ diagnostic­ criteria­ for­ BBS5.­ After­ obtaining­
informed­consent,­a­DNA­chip­study­was­performed­
at­Asper­Biotech­Ltd.­(Tartu,­Estonia).­The­DNA­chip­
(version­ 5)­ covered­ 305­ mutations­ from­ 14­ genes­
causative­for­BBS­and­related­diseases­(BBS1,­BBS2,­
BBS3,­ BBS4,­ BBS5,­ BBS6,­ BBS7,­ BBS8,­ BBS9,­
BBS10,­BBS12,­PHF6,­ALMS1,­and­GNAS1),­but­
identified­no­pathological­alterations.­Nevertheless,­
because­about­one­fifth­of­patients­with­clinically­def-
inite­BBS­have­no­identifiable­mutations­as­described­
above and because the chip covered only mutations 
previously reported to be pathogenic, these results 
could not rule out the possibility of a diagnosis of 
BBS in our family.
Tests for Renal Morphology and 
Function, and Other Laboratory Tests
To  detect  morphological  renal  abnormalities, 
the­ patients­ underwent­ abdominal­ CT­ scans­ and­
­ abdominal­sonography,­with­no­apparent­­ anomalies.­
Blood  and  urine  tests  routinely  performed  in 
Japan­ failed­ to­ identify­ any­ obvious­ abnormali-
ties (Table­1,­upper­rows).­Other­laboratory­data­
of the elder and younger patients included normal 
blood­sugar­­ levels­(78­mg/dl­and­81­mg/dl,­respec-
tively),­­ normal­total­cholesterol­levels­(144­mg/dl­
and­131­mg/dl,­­ normal­120–220­mg/dl),­unelevated­
triglyceride­levels­(28­mg/dl­and­72­mg/dl,­normal­
30–150­mg/dl),­­ negative­serum­CRP,­and­negative­
urine­occult­blood­or­glucose.­Creatinine­was­mea-
sured by an enzymatic method. Serum cystatin C 
Table 1. Results of sensitive renal function tests.
patient # 1 2
BUN (mg/dl) 7 9
Cre (mg/dl) 0.6 0.8
Urine protein - ∼ ± -
Urine albumin  
(with cre correction  
normal = ,10)
248* 5.2
Cystation C (0.63–0.95 mg/l) 0.96* 0.97*
note: *Abnormal values.elevated cystatin C levels in BBS 
Clinical Medicine Insights: Case Reports 2011:4  19
and­urine­albumin­were­then­examined.­­ Cystatin­C­
was­ measured­ by­ a­ colloidal­ gold­ agglutination­
method.­The­ results­ showed­ ­ elevated­ cystatin­ C­
  concentrations  in  both  patients  and  microalbu-
minuria in the elder patient (Table­1,­lower­rows).­
  Cystatin C   levels of the   age- and   sex-matched con-
trols­were­also­examined,­the­result­of­which­showed­
0.86­mg/L­for­an­elder­control­and­0.91­mg/L­for­a­
younger control.
Discussion
We describe abnormal levels of serum   cystatin C 
in­ two­ patients­ with­ BBS­ (Table­ 1).­ ­ Cystatin­ C­
is­ a­ plasma­ protein­ with­ a­ molecular­ weight­ of­
13.4­ kDa­ and­ belongs­ to­ the­ cysteine­ protease­
inhibitors.8 It is constantly synthesized in all types 
of­cells,­excreted­into­plasma,­and­filtered­com-
pletely  by  the    glomeruli.  Consequently,  increas-
ing serum levels of this marker indicate decreasing 
GFR.­­ Measurement­of­cystatin­C­more­sensitively­
detects­mild­GFR­­ abnormalities­than­that­of­crea-
tinine, a more common but less   sensitive marker 
of­ GFR,8­ probably­ because­ the­ lower­ ­ molecular­
weight­of­creatinine­(113­Da)­­ facilitates­its­easier­
­ filtration­in­the­glomeruli.­In­­ addition­to­the­sen-
sitivity, cystatin C is a more reliable marker than 
creatinine for detection of chronic renal disease, 
since creatinine levels are affected by many extra-
renal patient-  related factors such as muscle mass 
and consumption of cooked meat that is a source of 
creatinine.8­Our­patients­had­only­mild­increases­in­
cystatin­C.­Nevertheless,­because­cystatin­C­­ levels­
age-dependently­ increase­ with­ decreasing­ GFR,­
the­values­of­our­young­patients­seem­sufficiently­
high for their ages.8
A­urine­albumin­level­increased­only­in­the­elder­
patient.­ Patients­ with­ BBS­ occasionally­ ­ manifest­
proteinuria,7  suggesting  that  patients  had  not  only 
decreased­GFR­but­also­increased­­ protein­­ leakage.­
Urine­ albumin­ is­ used­ to­ detect­ early­ phases­ of­
  diabetic  or  hypertensive  nephropathy.9  Because 
­ neither­of­our­patients­showed­apparent­­ proteinuria,­
the elder patient may be in an early phase of   protein 
leakage.  In    diabetes  mellitus,  timely  treatment 
with­ an­ ­ angiotensin-converting­ enzyme­ ­ inhibitor,­
  independently of rise in arterial blood   pressure, is 
  considered  if  improvement  of    glycaemic    control 
and  moderate  decrease  of  dietary  protein  intake 
for­ 6–12­ months­ have­ failed­ to­ reduce­ the­ albu-
min    excretion  rate.9  Screening  programs  for 
  microalbuminuria  and  early  intervention  can  sub-
stantially  modify  the    natural  history  of  diabetic 
renal involvement and disease and possibly reduce 
the  incidence  of  end-stage  renal   failure.9  In  BBS, 
although such intervention has not been tested yet, 
we­may­consider­similar­protective­methods­for­renal­
dysfunction.
In­ conclusion,­ patients­ who­ have­ BBS­ with­
  apparently  normal  kidney  functions  may  have 
  abnormal levels of cystatin C, facilitating an early 
detection of kidney dysfunctions that might be   helpful 
for­ prompt­ correct­ diagnosis­ of­ BBS.­ ­ However,­
because our study is based on the results of the small 
number­ of­ patients,­ conclusion­ must­ await­ further­
studies.
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